R. Jonathan Henderson, MD, presented “Genetics and Genomic Biomarkers: How Molecular Markers and mpMRI Play a Role” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Henderson, R. Jonathan. “Genetics and Genomic Biomarkers: How Molecular Markers and mpMRI Play a Role” January 23rd, 2020. Accessed May 2022. https://dev.grandroundsinurology.com/genetics-and-genomic-biomarkers-how-molecular-markers-and-mpmri-play-a-role/
Genetics and Genomic Biomarkers: How Molecular Markers and mpMRI Play a Role – Summary:
R. Jonathan Henderson, MD, a urologist with Regional Urology, LLC, and President-Elect of the LUGPA Board of Directors, discusses the challenges posed by having a plethora of screening tools at a physician’s disposal, as well as how the statistical validity of these tools makes it unclear as to which are best for a given situation. He also uses his personal experience with taking a patient through the prostate cancer screening process in order to highlight the need for free and open communication with the patient, the importance of choosing a process that the physician is comfortable with, and the challenge of helping the patient find peace of mind.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Henderson gave this presentation during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.